ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos ETM-30-3-12927 10.3892/etm.2025.12927 Articles Association of serum proinflammatory factors with clinical response to ranibizumab for diabetic macular edema GaoXin 1 * LiHaosheng 2 * DiaoJiale 1 * LiuDianjun 3 SunWeifeng 4 ZhouZhe 1 Department of Ophthalmology, People's Liberation Army Naval Medical Center, Shanghai 200050, P.R. China Department of General Medicine, Chinese People's Liberation Army Unit Hospital 94162, Xi'an, Shaanxi 710600, P.R. China Department of Ophthalmology, Chinese People's Liberation Army Unit Hospital 92493, Huludao, Liaoning 710600, P.R. China Department of Ophthalmology, Shanghai Changhai Hospital, Navy Military Medical University, Shanghai 200433, P.R. China Correspondence to: Professor Zhe Zhou, Department of Ophthalmology, People's Liberation Army Naval Medical Center, 338 Huaihai West Road, Changning, Shanghai 200050, P.R. China zhouzhe1212@163.com Dr Weifeng Sun, Department of Ophthalmology, Shanghai Changhai Hospital, Navy Military Medical University, 168 Changhai Road, Yangpu, Shanghai 200433, P.R. China13817834960@163.com

*Contributed equally

 092025 21072025 30 3 177 15 10 2024 18 06 2025 Copyright: © 2025 Gao et al. 2025 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The present study aimed to investigate the role of circulating plasma inflammatory factors as predictors for the clinical response to anti-vascular endothelial growth factor (VEGF) injections in patients with diabetic macular edema (DME). An observational clinical study was conducted with 58 participants confirmed to have DME involving the foveal center. Participants with a central retinal thickness (CRT) of 320 µm or greater were treated with intravitreal Ranibizumab. CRT, best-corrected visual acuity (BCVA) and vessel density were assessed at 3-month intervals during follow-up. The mean LogMAR BCVA significantly improved from 0.88±0.50 at baseline to 0.681±0.491 at month 3 (P<0.001), while the CRT value decreased from 568.66±105.87 µm at baseline to 450.26±90.22 µm at month 3 (P<0.001). Of the cases, 62.07% showed a favorable anatomic response and 46.55% exhibited a favorable visual acuity response. IL-17 was linked to a limited anatomic response (P=0.02) and also negatively correlated with a favorable BCVA response (P=0.018). Similar associations were observed for IL-8, which was associated with a limited anatomic response (P<0.001) and was negatively associated with a favorable BCVA response (P=0.023). Cases that improved by at least two visual acuity lines had notably lower intercellular adhesion molecule (ICAM)-1 concentrations (P=0.046). Multivariate logistic regression analysis identified IL-17 and IL-8 as independent risk factors significantly associated with CRT (IL-17, P=0.003; IL-8, P=0.043), while IL-17 and ICAM-1 were independent risk factors significantly associated with BCVA (IL-17, P=0.030; ICAM-1, P=0.029). In conclusion, elevated levels of serum IL-17, IL-8 and ICAM-1 at baseline are linked to a restricted clinical response to anti-VEGF therapy for DME.

 ranibizumab diabetic macular edema IL-17 IL-8 prognostic Funding: This study was funded by the Clinical Innovation Program of the People's Liberation Army Naval Medical Center, Shanghai (grant no. 22TSJS11). Introduction

Diabetic retinopathy (DR) is one of the most frequent complications of diabetes that can result in significant consequences, including rapid and irreversible vision loss among the working population (1,2). DR is divided into three categories: No DR, non-proliferative DR (NPDR) and PDR (3). Diabetic macular edema (DME) is recognized as a neurovascular complication of DR with the involvement of inflammatory processes and is the main cause of vision loss in patients with DR (4-6). Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents has been the main treatment for DME (7,8). These treatments may have potential risks, such as retinal detachment and lens damage, and may not be successful for all individuals (9-11). Therefore, further research on the mechanisms of DME progression is essential to develop new and more effective therapeutic approaches for this condition.

Prolonged hyperglycemia is known to activate pro-inflammatory cascades, which plays a significant role in the pathological responses of DME (12,13). A growing body of evidence supports the presence of a subclinical proinflammatory state in type 2 diabetic patients, as indicated by elevated serum levels of C-reactive protein and other inflammatory cytokines (14,15). In addition to VEGF, various cytokines such as interleukin 6 (IL-6), IL-8, IL-17, intercellular adhesion molecule 1 (ICAM-1, CD54) and interferon-γ have also been implicated (16-19). In conditions of high blood sugar, Müller cells in the retina secrete more IL-17A, potentially leading to functional impairment of Müller cells and worsening diabetes-induced retinal vascular issues and ganglion cell apoptosis (20,21). ICAM-1 plays a significant role in inflammatory responses and the interplay of immune cells in the pathological mechanisms associated with chronic ocular inflammation. The upregulation of ICAM-1 contributes to endothelial cell damage, leukocyte adhesion, hypoxia and disruption of the blood-retinal barrier-all pivotal events in the development of DME (22,23). These pieces of evidence indicate that inflammatory cytokines play an important role in the development, progression and prognosis of DME.

The present study aimed to explore the potential relationship between levels of circulating plasma inflammatory factors and the pattern of macular thickness response. In addition, the research explored the enhancement of visual acuity in patients with DME who underwent anti-VEGF treatment in a practical clinical environment.

 Patients and methods <sec> <title>Study population

This observational clinical research enrolled 58 diabetic patients who were hospitalized at the People's Liberation Army (PLA) Naval Medical Center (Shanghai, China) for intravitreal injection treatment from January 2021 to January 2023. Participants met eligibility criteria and underwent an initial baseline disease correlation phase. Diabetic retinopathy severity was graded using the International Clinical Diabetic Retinopathy Disease Severity Scale (24). The following inclusion criteria were applied: Age ≥18 years with type II diabetes mellitus (DM2) and NPDR (if both eyes met the requirements, one eye was randomly included), and optical coherence tomography (OCT) confirmed DME involving the foveal center with a central retinal thickness (CRT) ≥320 µm. The exclusion criteria were as follows: i) Patients who had received laser, anti-VEGF therapy or triamcinolone treatment in the previous 6 months; ii) patients with acute metabolic disorders such as ketoacidosis or hyperosmolar syndrome; iii) patients with a history of cardiocerebrovascular disease, valvular heart disease, stroke, peripheral arterial disease, abnormal liver or kidney function or pregnancy; and iv) patients with uncontrolled hypertension (defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at baseline); however, patients with controlled hypertension (systolic blood pressure <160 mmHg and diastolic blood pressure <100 mmHg) were included and adjusted for in the analysis.

 Study design

This was an observational, cross-sectional study directed to measure serum levels of cytokines and growth factors in patients with DME who were consecutively recruited at the PLA Naval Medical Center (Shanghai, China). The study protocol received approval from the Ethics Committee of the PLA Naval Medical Center (on December 6th, 2020; approval no., AF-HEC-071). All study procedures complied with the principles set forth in the Declaration of Helsinki and written informed consent was obtained from all participants prior to their enrollment in the study.

The primary outcome measure of the present study was the correlation between serum mediator levels and the severity grade of DME as defined by spectral-domain (OCT) measurements of CRT. Other evaluation parameters included best-corrected visual acuity (BCVA), superficial vascular complex (SVC) and deep vascular complex (DVC). Additionally, the study evaluated differences in serum cytokine and growth factor levels between the DME and non-DME groups as a secondary outcome.

 Study intervention

All study participants received a monthly intravitreal ranibizumab (Novartis Pharmaceuticals) 0.5 mg/0.05 ml injection 3.5-4 mm from the corneal limbus at baseline, for 3 months (baseline, and 1 month and 2 months after baseline). Serum samples were collected at baseline and week 8, and at the 2-month follow-up, immediately after the third intravitreal injection of ranibizumab. Participants were followed up 3 months after baseline and anatomical response was assessed 1 month after the third and final injection of the study.

 Evaluation procedures

All participants underwent a forearm venous puncture for peripheral blood extraction and samples were collected from a peripheral vein in two 8-ml serum tubes. These tubes were gently inverted for good mixing and sat upright for 30 min before centrifuging. The centrifuge was run at 1,000 x g for 10 min at 12˚C, 750-µl serum samples were transferred to a sterile tube and then stored at -80˚C, and enzyme-linked immunosorbent assay (ELISA) was performed using specific enzyme-linked immunosorbent assay kits [IL-17A, cat. no. RAB0262; IL-8, cat. no. RAB0318; placental growth factor, cat. no. RAB0149; VEGF, cat. no. RAB0507; transforming growth factor β2, cat. no. RAB0416; ICAM-1, cat. no. RAB0220; IL-6, cat. no. RAB0308; IL-10, cat. no. RAB0244; vascular intercellular adhesion molecule-1, cat. no. RAB0025; monocyte chemoattractant protein (MCP1), cat. no. RAB0056; IL-1β, cat. no. RAB0273; Sigma-Aldrich; Merck KGaA] according to the manufacturer's instructions.

 Statistical analysis

All data were analyzed using SPSS (version 23; IBM Corp.). Normality of continuous variables was assessed using the Shapiro-Wilk test. Mean values across response categories were compared using either the independent-samples T-test or the Mann-Whitney U-test. Linear correlations between systemic factors and quantitative and qualitative outcomes were evaluated at each follow-up point by calculating Pearson or Spearman correlation coefficients (R). Further examination of significant associations was conducted using multiple linear regression or binary logistic regression. P<0.05 was regarded to indicate statistical significance. To minimize the occurrence of false-positive results, the Benjamini-Hochberg procedure was applied to all significant P-values to adjust for the anticipated false discovery rate. Multiple linear regression models were used to assess independent associations between BCVA and predictor variables. The model included adjustments for age, sex and diabetes duration.

 Results <sec> <title>Patient characteristics

A total of 69 diabetic patients were recruited for the original baseline study from January 2021 to January 2023 at the PLA Naval Medical Center and 58 participants proceeded to follow-up. The mean age was 66.12±7.28 years and 37 participants (63.8%) were female. The mean baseline LogMAR BCVA was 0.88±0.50 and the OCT CRT was 568.66±105.87 µm. The mean SVC was 0.32±0.06 and the mean DVC was 0.33±0.07. A total of 19 patients (32.8%) had a DM2 duration of ≥20 years, 28 patients (48.3%) were classified as PDR according to the International Clinical Diabetic Retinopathy Disease Severity Scale and 39 patients (67.2%) had previously received laser therapy (Table I).

 Treatment responses

Table II summarizes the clinical responses of the patients to ranibizumab treatment. The mean LogMAR BCVA was improved from 0.875±0.504 at baseline to 0.681±0.491 at month 3 (P<0.001) and the CRT value had declined from 568.66±105.87 µm at baseline to 450.26±90.22 at month 3 (P<0.001).

Table III lists the data according to anatomic response categories. The changes in CRT between baseline and month 3 were used to classify patients into responders and non-responders. A total of 36 patients (62.07%) had a favorable anatomical response (CRT reduction ≥20%), and no response (<20% reduction in CRT) was found in 22 cases (37.93%) at the 3-month follow-up.

Visual acuity ≤0.6 was found in 16 cases (27.59%) at baseline, improving to 36 (62.07%) cases at the 3rd month. An improvement in visual acuity of at least 2 lines was regarded as a ‘response’, and such a ‘response’ was seen in 27 cases (46.55%) at 3 months. There was no significant change in SVC and DVC. Table IV presents the information based on the qualitative outcomes of visual acuity.

 Association of systemic factors and macular outcomes

Significant correlations were found between baseline IL-17 and IL-8 concentrations and CRT. In the group with a favorable anatomic response, the level of IL-17 was 9.31±1.16 ng/l, while in the no anatomic response group, the level of IL-17 was 10.27±1.61 ng/l (P=0.02). A similar difference was found for IL-8, where the level in the favorable response group was 17.05±22.09 ng/l, and in the no anatomic response group, it was 34.50±28.62 ng/l (P<0.001). No significant differences were found in IL-6, IL-10, IL-1β, ICAM-1 and MCP1 (Table III). Multivariate logistic regression analysis revealed that both IL-17 and IL-8 were independent risk factors significantly associated with CRT (IL-17, P=0.003; IL-8, P=0.043; Table V). As in the multivariate linear regression, significant correlations were found for CRT and IL-17 (P=0.001, R2=0.409), as well as CRT and IL-8 (P=0.029, R2=0.288), in the scatter plots (Fig. 1A and B).

 Association of systemic factors and visual outcomes

Significant correlations were found between the baseline concentration of IL-17 or IL-8 and ICAM-1 or BCVA. In the group with a favorable BCVA response, the level of IL-17 was 9.20±1.28 ng/l, while in the no BCVA response group, the level of IL-17 was 10.10±1.41 ng/l (P=0.018). IL-8 showed the same trend, as the level of IL-8 in the ‘response’ group and ‘no response’ group was 16.95±18.14 and 29.52±30.33 ng/l, respectively (P=0.023). The outcome was achieved with a significant decrease in the ICAM-1 concentration, as BCVA response of at least two sight lines improved (724.97±96.42 vs. 787.81±126.37 pg/ml, P=0.046; Table IV). Multivariate logistic regression analysis revealed that both IL-17 and ICAM-1 were independent risk factors significantly associated with BCVA (IL-17, P=0.030; ICAM-1, P=0.029) (Table V). As in the multivariate linear regression, significant effects were found for BCVA and IL-17 (P=0.008, R2=0.343), and BCVA and ICAM-1 (P=0.008, R2=0.344), in the correlation plots (Fig. 2A and B).

 Discussion

The present study investigated the clinical response and influencing factors in patients with diabetic retinopathy undergoing ranibizumab treatment. A total of 58 patients were followed up, revealing a decrease in the CRT value from 568.66±105.87 µm at baseline to 450.26±90.22 at 3 months (P<0.001), and an improvement in the average LogMAR BCVA from 0.88±0.50 at baseline to 0.681±0.491 (P<0.001), indicating significant progress. The analysis of systemic factors and clinical outcomes revealed a notable negative correlation between IL-17 or IL-8 concentrations and CRT recovery through multivariate logistic regression. Regarding visual outcomes, concentrations of IL-17, IL-8 and ICAM-1 were significantly associated with BCVA improvement. In the multivariate linear regression, IL-17 and ICAM-1 were identified as risk factors linked to poor BCVA improvement in patients with diabetic retinopathy.

In the assessment of diabetic retinopathy recovery, CRT and BCVA are two key indicators that reflect the patient's visual function status and the extent of the disease. They are crucial for evaluating treatment effectiveness. CRT is defined as the average thickness of the retina between its inner and outer boundaries in the central 1 mm area of all scans performed, and is one of the most commonly used indicators in OCT. In diabetic patients, long-term high blood sugar and changes in blood components can lead to damage to the blood-retinal barrier, causing necrosis of retinal capillary pericytes and endothelial dysfunction. This results in leakage of fluid components from the blood vessels into the retinal gap, leading to changes in retinal tissue such as bleeding, edema and exudation, all of which can increase CRT (25). CRT plays an important role in evaluating the recovery of DME. Monitoring changes in retinal thickness can help detect lesions in a timely manner, assess the trend of disease progression, evaluate treatment effectiveness and guide adjustments in subsequent treatment. In addition, BCVA is an important indicator for assessing visual function status. DME often leads to decreased visual acuity and improvement in BCVA indicates improvement in visual function during the recovery process. By monitoring changes in BCVA, treatment effectiveness can be more intuitively understood and treatment plans can be adjusted promptly to promote the recovery of visual function in patients.

IL-17 is a family of cytokines that includes IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. IL-17A, primarily produced by T helper (Th) 17 cells, an independent lineage of CD4+ T cells, is closely associated with various inflammatory cytokines and has been linked to the development of autoimmune and inflammatory diseases (26,27). Specifically, IL-17A has been implicated in the pathogenesis of diabetes, as it is upregulated in peripheral blood mononuclear cells and plasma from patients with PDR (21,28,29). Additionally, IL-17A has been found to disrupt barriers by compromising the integrity of endothelial cell monolayers and disrupting junction proteins (30,31), thus playing a crucial role in the initiation and progression of diabetic retinopathy (32), Limited research has investigated the influence of circulating IL-17A on diabetic retinopathy prognosis following Ranibizumab treatment. The present study investigated the relationship between circulating IL-17A levels and clinical outcomes in diabetic retinopathy patients. The results showed that higher baseline IL-17 levels were associated with a poorer prognosis in terms of BCVA and CRT. This association may be attributed to the enduring impairment of endothelial cell integrity and retinal barrier function induced by elevated IL-17 levels within the system.

ICAM-1 is a crucial molecular mediator that facilitates the migration of Th17 cells among human retinal vascular endothelial cells (33). ICAM-1 has the potential to stimulate angiogenesis and act as a biomarker for endothelial cell activation or injury (34). Previous studies have indicated that ICAM-1 expression in diabetic patients may increase with the progression of DME, potentially correlating with the severity of DR (35,36). A meta-analysis further demonstrated elevated levels of ICAM-1 in patients with DME, regardless of the diabetes type, with a potential link to DME severity (37). However, a prospective study suggested that while ICAM-1 may be associated with the development of retinal hard exudates, it may not be linked to DR progression (18). This highlights the ongoing uncertainty surrounding the role of ICAM-1 in DR development. In the present study, it was observed that higher baseline ICAM-1 levels were associated with an unfavorable prognosis for BCVA in patients with DME. Furthermore, multivariate linear regression analysis identified ICAM-1 as a risk factor for poor BCVA improvement in patients with DR.

IL-8, an essential chemokine, plays a significant role in various inflammatory diseases and angiogenesis (38,39). There is strong evidence indicating that IL-8 not only contributes to the development of DME, but also correlates with more severe stages of the disease, particularly in PDR and DME (17,40,41). The present research consistently found that higher baseline levels of IL-8 were linked to poor prognosis for CRT and BCVA in patients with DR. Additionally, through multivariate linear regression analysis, IL-8 was identified as a risk factor for limited CRT improvement in patients with DME. Therefore, targeting IL-8 intervention may emerge as a novel strategy for managing diabetic retinopathy.

The present study has certain limitations. First, the results are based on data from a single clinical center, which may not be fully representative of treatment practices globally due to the limited number and diversity of ethnicities included; the study's single institution setting limited the diversity of the cohort in terms of age, sex and DR stage. Therefore, future research will need to utilize larger and more diverse datasets for analysis. In addition, only systematic factors were assessed at baseline, overlooking potential variations in individual cytokine levels at different time-points. Despite these limitations, this study presents compelling evidence that serum biomarkers are correlated with unfavorable clinical outcomes in patients with DR.

In conclusion, the present findings suggest that individuals with elevated levels of serum IL-17, IL-8 and ICAM-1 may have a reduced clinical response to ranibizumab monotherapy. The presence of serum inflammatory factors could potentially influence the effectiveness of anti-VEGF treatment, highlighting the importance of further research into optimizing current treatment approaches.

 Acknowledgements

Not applicable.

 Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

 Authors' contributions

XG was involved in the conceptualization, methodology, investigation, formal analysis and writing the original draft. HL performed data curation, writing of the original draft and language editing. JD contributed with visualization and investigation. DL was responsible for data analysis and revising the manuscript (for intellectual content). WS helped with study design and provided general supervision. ZZ was involved in study design, visualization and writing, reviewing and editing the manuscript. All authors have read and approved the final manuscript. XG and ZZ confirm the authenticity of all the raw data.

 Ethics approval and consent to participate

The research methods followed the guidelines established by the Declaration of Helsinki. Ethics approval was obtained from the Ethics Committee of the PLA Naval Medical Center (Shanghai, China; approval no. AF-HEC-071). Written informed consent was obtained from all individual participants included in the study.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declared that they have no competing interests.

 References American Diabetes Association11. microvascular complications and foot care: Standards of medical care in diabetes-2021Diabetes Care44 (Suppl 1)S151S16720213329842210.2337/dc21-S011 CheungNMitchellPWongTYDiabetic retinopathyLancet37612413620102058042110.1016/S0140-6736(09)62124-3 WangZTangJJinEZhongYZhangLHanXLiuJChengYHouJShiXSerum untargeted metabolomics reveal potential biomarkers of progression of diabetic retinopathy in asiansFront Mol Biosci987129120223575582310.3389/fmolb.2022.871291 PeddadaKVBrownAVermaVNebbiosoMTherapeutic potential of curcumin in major retinal pathologiesInt Ophthalmol3972573420192940486110.1007/s10792-018-0845-y SemeraroFMorescalchiFCancariniARussoARezzolaSCostagliolaCDiabetic retinopathy, a vascular and inflammatory disease: Therapeutic implicationsDiabetes Metab4551752720193100575610.1016/j.diabet.2019.04.002 AntonettiDAKleinRGardnerTWDiabetic retinopathyN Engl J Med3661227123920122245541710.1056/NEJMra1005073 StittAWCurtisTMChenMMedinaRJMcKayGJJenkinsAGardinerTALyonsTJHammesHPSimóRLoisNThe progress in understanding and treatment of diabetic retinopathyProg Retin Eye Res5115618620162629707110.1016/j.preteyeres.2015.08.001 BoyerDSHopkinsJJSorofJEhrlichJSAnti-vascular endothelial growth factor therapy for diabetic macular edemaTher Adv Endocrinol Metab415116920132432485510.1177/2042018813512360 LinTWChienYLinYYWangMLYarmishynAAYangYPHwangDKPengCHHsuCCChenSJChienKHEstablishing liposome-immobilized dexamethasone-releasing PDMS membrane for the cultivation of retinal pigment epithelial cells and suppression of neovascularizationInt J Mol Sci2024120193063444810.3390/ijms20020241 ChoiAYChoHKimYCEffect of two different doses of intravitreal bevacizumab with temporal retina-sparing laser photocoagulation for retinopathy of prematurityInt J Ophthalmol1116616920182937600710.18240/ijo.2018.01.26 HeiduschkaPPlagemannTLiLAlexAFEterNDifferent effects of various anti-angiogenic treatments in an experimental mouse model of retinopathy of prematurityClin Exp Ophthalmol47798720193007376910.1111/ceo.13368 SophieRLuNCampochiaroPAPredictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumabOphthalmology1221395140120152587007910.1016/j.ophtha.2015.02.036 WangQNavitskayaSChakravarthyHHuangCKadyNLydicTAChenYEYinKJPowellFLMartinPMDual anti-inflammatory and anti-angiogenic action of miR-15a in diabetic retinopathyEBioMedicine1113815020162753157510.1016/j.ebiom.2016.08.013 Temelkova-KurktschievTHenkelEKoehlerCKarreiKHanefeldMSubclinical inflammation in newly detected type II diabetes and impaired glucose toleranceDiabetologia4515120021184523510.1007/s125-002-8256-1 PradhanADMansonJERifaiNBuringJERidkerPMC-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitusJAMA28632733420011146609910.1001/jama.286.3.327 HillierRJOjaimiEWongDTMakMYKBergerARKohlyRPKertesPJForooghianFBoydSREngKAqueous humor cytokine levels and anatomic response to intravitreal ranibizumab in diabetic macular edemaJAMA Ophthalmol13638238820182952214410.1001/jamaophthalmol.2018.0179 PessoaBHeitorJCoelhoCLeanderMMenéresPFigueiraJMeirelesABeirãoMSystemic and vitreous biomarkers-new insights in diabetic retinopathyGraefes Arch Clin Exp Ophthalmol2602449246020223532528610.1007/s00417-022-05624-7 MuniRHKohlyRPLeeEQMansonJESembaRDSchaumbergDAProspective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trialJAMA Ophthalmol13151452120132339239910.1001/jamaophthalmol.2013.2299 LiJZhaoTSunYInterleukin-17A in diabetic retinopathy: The crosstalk of inflammation and angiogenesisBiochem Pharmacol22511631120243878895810.1016/j.bcp.2024.116311 QiuAWBianZMaoPALiuQHIL-17A exacerbates diabetic retinopathy by impairing Müller cell function via Act1 signalingExp Mol Med48e28020162798034310.1038/emm.2016.117 QiuAWLiuQHWangJLBlocking IL-17A alleviates diabetic retinopathy in rodentsCell Physiol Biochem4196097220172822244510.1159/000460514 JonasJBTaoYNeumaierMFindeisenPMonocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degenerationArch Ophthalmol1281281128620102093799710.1001/archophthalmol.2010.227 MiyamotoKKhosrofSBursellSEMoromizatoYAielloLPOguraYAdamisAPVascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1)Am J Pathol1561733173920001079308410.1016/S0002-9440(10)65044-4 HanedaSYamashitaHInternational clinical diabetic retinopathy disease severity scaleNihon Rinsho68 (Suppl 9)S228S235201021661159(In Japanese) BaiJYangFWangRYanQGhrelin ameliorates diabetic retinal injury: Potential therapeutic avenues for diabetic retinopathyOxid Med Cell Longev2021804329920213473784610.1155/2021/8043299 GaffenSLRecent advances in the IL-17 cytokine familyCurr Opin Immunol2361361920112185208010.1016/j.coi.2011.07.006 ZhongHSunXContribution of interleukin-17A to retinal degenerative diseasesFront Immunol1384793720223539208710.3389/fimmu.2022.847937 YanAZhangYWangXCuiYTanWInterleukin 35 regulates interleukin 17 expression and T helper 17 in patients with proliferative diabetic retinopathyBioengineered13132931329920223563503210.1080/21655979.2022.2080367 MarwahaAKCromeSQPanagiotopoulosCBergKBQinHOuyangQXuLPriatelJJLevingsMKTanRCutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetesJ Immunol1853814381820102081098210.4049/jimmunol.1001860 SetiadiAFAbbasARJeetSWongKBischofAPengILeeJBremerMEggersELDeVossJIL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosisJ Neuroimmunol33214715420193103496210.1016/j.jneuroim.2019.04.011 ElahiRNazariMMohammadiVEsmaeilzadehKEsmaeilzadehAIL-17 in type II diabetes mellitus (T2DM) immunopathogenesis and complications; molecular approachesMol Immunol171667620243879568610.1016/j.molimm.2024.03.009 ZapadkaTELindstromSITaylorBELeeCATangJTaylorZRRHowellSJTaylorPRRORγt Inhibitor-SR1001 halts retinal inflammation, capillary degeneration, and the progression of diabetic retinopathyInt J Mol Sci21354720203242959810.3390/ijms21103547 BharadwajASSchewitz-BowersLPWeiLLeeRWSmithJRIntercellular adhesion molecule 1 mediates migration of Th1 and Th17 cells across human retinal vascular endotheliumInvest Ophthalmol Vis Sci546917692520132402201110.1167/iovs.13-12058 DingYYangCZhouZPengYChenJPanSXuHCaiYOuKXieWWangHClinical significance of soluble adhesion molecules in anti-NMDAR encephalitis patientsAnn Clin Transl Neurol694595320193113969210.1002/acn3.740 NowakMWielkoszyńskiTMarekBKos-KudłaBSwietochowskaESiemińskaLKajdaniukDGłogowska-SzelagJNowakKBlood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathyClin Exp Med815916420081879168910.1007/s10238-008-0173-z BlumAPastukhNSoceaDJabalyHLevels of adhesion molecules in peripheral blood correlat with stages of diabetic retinopathy and may serve as bio markers for microvascular complicationsCytokine106767920182913302610.1016/j.cyto.2017.10.014 YaoYDuJLiRZhaoLLuoNZhaiJYLongLAssociation between ICAM-1 level and diabetic retinopathy: A review and meta-analysisPostgrad Med J9516216820193110993410.1136/postgradmedj-2018-136102 BaronVTPioRJiaZMercolaDEarly growth response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancerBr J Cancer11275576420152563303510.1038/bjc.2014.622 AlfaroCSanmamedMFRodríguez-RuizMETeijeiraÁOñateCGonzálezÁPonzMSchalperKAPérez-GraciaJLMeleroIInterleukin-8 in cancer pathogenesis, treatment and follow-upCancer Treat Rev60243120172886636610.1016/j.ctrv.2017.08.004 OwenLAHartnettMESoluble mediators of diabetic macular edema: The diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edemaCurr Diab Rep1347648020132364994610.1007/s11892-013-0382-z LeeWJKangMHSeongMChoHYComparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusionBr J Ophthalmol961426143020122293068110.1136/bjophthalmol-2012-301913

Scatter plots for the correlation of baseline IL-17 and IL-8 vs. CRT change (month 3 - baseline) (A) Baseline IL-17 vs. CRT change (month 3 - baseline). (B) Baseline IL-8 vs. CRT change (month 3 - baseline). CRT, central retinal thickness.

Scatter plots for the correlation of baseline IL-17 and ICAM-1 vs. BCVA change (month 3 - baseline). (A) Baseline IL-17 vs. BCVA change (month 3 - baseline). (B) Baseline ICAM-1 vs. BCVA change (month 3 - baseline). BCVA, best corrected visual acuity; ICAM, intercellular adhesion molecule.

Baseline characteristics of the patients (n=58).

Characteristic Value Normal range
Sex    
     Male 21 (36.2)  
     Female 37 (63.8)  
Age, years 66.12±7.28  
Eye laterality    
     Left 25 (43.1)  
     Right 33 (56.9)  
Lens status    
     Intraocular lenses 29 (50.0)  
     Lenses 29 (50.0)  
Baseline BCVA logMAR 0.88±0.50  
Baseline CRT 568.66±105.87  
Baseline SVC 0.32±0.06  
Baseline DVC 0.33±0.07  
Diabetes duration, years    
     0-10 10 (17.2)  
     10-19 29 (50.0)  
     ≥20 19 (32.8)  
DR stage    
     NPDR 30 (51.7)  
     PDR 28 (48.3)  
Hypertension    
     Yes 40 (69.0)  
     No 18 (31.0)  
History of laser photocoagulation    
     Yes 39 (67.2)  
     No 19 (32.8)  
Glycated hemoglobin A1c, % 6.87±1.43 4.0-6.0
GLU, mmol/l 8.15±1.46 3.9-6.1
Urea, mg/dl 61.09±19.64 22-57
UA, µmol/l 260.31±77.13 149-416
Scr, µmol/l 69.43±19.70 53-106

Values are expressed as n (%) or the mean ± standard deviation. BCVA, best corrected visual acuity; CRT, central retinal thickness; SVC, superficial vascular complex; DVC, deep vascular complex; GLU, glucose; UA, uric acid; Scr, serum creatinine.

Changes in clinical characteristics from baseline to month 3.

Parameter Baseline Month 3 Mean change between baseline and month 3 P-value
BCVA, logMAR 0.875±0.504 0.681±0.491 0.194±0.245 (-0.222-1.176) <0.001
CRT, µm 568.66±105.87 450.26±90.22 118.40±62.06 (-15.0-242.0) <0.001
SVC 0.317±0.063 0.290±0.043 0.027±0.079 (-0.163-0.158) 0.0540
DVC 0.328±0.075 0.292±0.041 0.035±0.081 (-0.159-0.214) 0.0658

Values are expressed as the mean ± standard deviation (range). BCVA, best corrected visual acuity; CRT, central retinal thickness; SVC, superficial vascular complex; DVC, deep vascular complex.

Systematic basic laboratory data based on anatomical response patterns.

Parameter Response (n=36) No response (n=22) Total (n=58) P-value
IL 17, ng/l 9.31±1.16 10.27±1.61 9.68±1.41 0.020
IL 8, ng/l 17.05±22.09 34.50±28.62 23.67±25.97 <0.001
IL-6, ng/l 2.73±1.51 2.81±1.55 2.76±1.51 0.923
IL-10, ng/l 5.46±3.11 5.88±3.15 5.62±3.10 0.586
IL 1β, ng/l 3.66±1.68 3.23±1.61 3.49±1.65 0.361
ICAM-1, pg/ml 749.37±95.45 773.58±146.53 758.55±116.81 0.854
MCP1, ng/l 238.82±129.60 258.61±182.83 246.33±150.74 0.917

Values are expressed as the mean ± standard deviation. ICAM, intercellular adhesion molecule; MCP, monocyte chemoattractant protein.

Systematic baseline laboratory data based on visual acuity response patterns.

Parameter Response (N=27) No response (N=31) Total (N=58) P-value
IL-17, ng/l 9.20±1.28 10.10±1.41 9.68±1.41 0.018
IL-8, ng/l 16.95±18.14 29.52±30.33 23.67±25.97 0.023
IL-6, ng/l 2.64±1.47 2.86±1.56 2.76±1.51 0.714
IL-10, ng/l 5.50±3.42 5.73±2.85 5.62±3.10 0.483
IL-1β, ng/l 3.69±1.79 3.33±1.53 3.49±1.65 0.436
ICAM-1, pg/ml 724.97±96.42 787.81±126.37 758.55±116.81 0.046
MCP1, ng/l 220.95±118.58 268.43±172.92 246.33±150.74 0.201

Values are expressed as the mean ± standard deviation. ICAM, intercellular adhesion molecule; MCP, monocyte chemoattractant protein.

Multivariate linear regression model of change in disease severity.

    Changes in BCVA   Changes in CRT
Parameter β SE P-value β SE P-value
IL-17, ng/l -0.048 0.021 0.030 16.628 5.363 0.003
IL-8, ng/l -0.001 0.001 0.383 0.596 0.287 0.043
ICAM-1, pg/ml -0.001 0.0002 0.029 0.018 0.065 0.782
R2 0.2074     0.2312    

SE, standard error; ICAM, intercellular adhesion molecule; BCVA, best corrected visual acuity; CRT, central retinal thickness.